2-(氰基甲氧基)苯羧酸甲酯 | 1641-00-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(氰基甲氧基)苯羧酸甲酯
• 英文名称: (2-carbomethoxyphenoxy)acetonitrile
• 英文别名: Methyl 2-(cyanomethoxy)benzoate
• CAS: 1641-00-5
• 化学式: C₁₀H₉NO₃
• mdl: MFCD01924694
• 分子量: 191.186
• InChiKey: GMWTWTDYLCCEKF-UHFFFAOYSA-N

物化性质

• 熔点：
  53-55°C
• 沸点：
  179-181 °C(Press: 17 Torr)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2926909090
• 危险品运输编号：
  UN 3439
• 储存条件：
  存储条件：2-8°C，密封保存，并保持干燥。

反应信息

• 作为反应物：
  描述：

  2-(氰基甲氧基)苯羧酸甲酯 在 盐酸 、 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 palladium 10% on activated carbon 、 氢气 、 溴 、 sodium methylate 、 四丁基硫酸氢铵 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 醋酸异丙酯 、 水 、 溶剂黄146 、 甲苯 为溶剂， 30.0~65.0 ℃ 、379.22 kPa 条件下， 生成 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one
  参考文献：
  名称：

  PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS

  摘要：

  本公开提供了制备以下化合物的过程：这是一种选择性晚期钠电流抑制剂。该公开还提供了合成中间体化合物。

  公开号：

  US20150225384A1
• 作为产物：
  描述：

  溴乙腈 、 水杨酸甲酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以72.5%的产率得到2-(氰基甲氧基)苯羧酸甲酯
  参考文献：
  名称：

  联芳基羟基酮文库的组合合成和体外评估，作为抗MRSA的抗毒剂。

  摘要：

  抗生素抗性加上新抗生素的发展减少，因此有必要寻找新型抗菌剂。抗毒剂是常规抗生素的替代品。在这项工作中，我们报告了针对最广泛的细菌病原体耐甲氧西林金黄色葡萄球菌（MRSA）的小分子抗毒剂家族。结构-活性关系的研究导致了148位联芳基羟基酮库的简明合成方法的发展。酰化键形成过程提供间苯二酚（1）和芳氧基乙腈（2）作为合成子。进行路易斯酸活化的Friedel-Crafts酰化步骤，其中ZnCl2的腈官能度为2，然后亲核力为1，从而以优异的收率获得了联芳基羟基酮。大量产品结晶。此策略可在一个步骤中提供一系列联芳基羟基酮。这是第一个集体合成研究，它记录了通过单一合成操作对此类化合物的访问。该化合物在该文库中的体外功效通过兔红细胞溶血试验评估。与不存在该化合物的对照相比，最有效的化合物4f-12抑制溶血98.1 +/- 0.1％。

  DOI：

  10.1021/co400142t

文献信息

• [EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER AU MOYEN D'AMIDES D'ACIDE O-AMINO-ALCANOIQUE A SUBSTITUTIONS AROMATIQUES ET DE DIAMIDES D'ACIDE ALCANOIQUE
  申请人：ELAN PHARM INC

  公开号：WO2003103652A1

  公开（公告）日：2003-12-18

  Disclosed.are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R1, R2, R3, R4, R5, X1, and X2 are defined herein.

  披露了治疗阿尔茨海默病和其他疾病，和/或抑制β-分泌酶酶，和/或通过使用式(I)化合物在哺乳动物体内抑制Aβ肽沉积的方法，其中变量R1、R2、R3、R4、R5、X1和X2在此处定义。
• [EN] MACROCYCLIC COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF<br/>[FR] COMPOSÉS MACROCYCLIQUES POUR L'INHIBITION DE L'ACTIVITÉ DE L'INDOLÉAMINE -2,3-DIOXYGÉNASE ET LEUR UTILISATION
  申请人：ENSEMBLE THERAPEUTICS CORP

  公开号：WO2018053302A1

  公开（公告）日：2018-03-22

  The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of indoleamine-2,3-dioxygenase (IDO) activity, and methods of treating IDO-related disorders.

  本发明涉及化合物及其药用可接受的组合物，用作吲哌酸胺-2,3-二氧化酶（IDO）活性的拮抗剂，并用于治疗与IDO相关的疾病的方法。
• Optimizations in the preparation of the first benzimidazolyl salicylic acid derivative. An efficient one-pot synthesis of 2-[(2'-carbomethoxyphenoxy)methyl]benzimidazole
  作者：Nabeel A. R. Nabulsi、Richard D. Gandour

  DOI：10.1021/jo00006a059

  日期：1991.3
• Docking studies of benzylidene anabaseine interactions with α7 nicotinic acetylcholine receptor (nAChR) and acetylcholine binding proteins (AChBPs): Application to the design of related α7 selective ligands
  作者：David C. Kombo、Anatoly Mazurov、Kartik Tallapragada、Philip S. Hammond、Joseph Chewning、Terry A. Hauser、Montserrat Vasquez-Valdivieso、Daniel Yohannes、Todd T. Talley、Palmer Taylor、William S. Caldwell

  DOI：10.1016/j.ejmech.2011.09.033

  日期：2011.11

  AChBPs isolated from Lymnaea stagnalis (Ls), Aplysia californica (Ac) and Bulinus truncatus (Bt) have been extensively used as structural prototypes to understand the molecular mechanisms that underlie ligand-interactions with nAChRs [1]. Here, we describe docking studies on interactions of benzylidene anabaseine analogs with AChBPs and alpha 7 nAChR. Results reveal that docking of these compounds using Glide software accurately reproduces experimentally-observed binding modes of DMXBA and of its active metabolite, in the binding pocket of Ac. In addition to the well-known nicotinic pharmacophore (positive charge, hydrogen-bond acceptor, and hydrophobic aromatic groups), a hydrogen-bond donor feature contributes to binding of these compounds to Ac. Bt, and the alpha 7 nAChR. This is consistent with benzylidene anabaseine analogs with OH and NH2 functional groups showing the highest binding affinity of these congeners, and the position of the ligand shown in previous X-ray crystallographic studies of ligand-Ac complexes. In the predicted ligand-Ls complex, by contrast, the ligand OH group acts as hydrogen-bond acceptor. We have applied our structural findings to optimizing the design of novel spirodiazepine and spiroimidazoline quinuclidine series. Binding and functional studies revealed that these hydrogen-bond donor containing compounds exhibit improved affinity and selectivity for the alpha 7 nAChR subtype and demonstrate partial agonism. The gain in affinity is also due to conformational restriction, tighter hydrophobic enclosures, and stronger cation-pi interactions. The use of AChBPs structure as a surrogate to predict binding affinity to alpha 7 nAChR has also been investigated. On the whole, we found that molecular docking into Ls binding site generally scores better than when a alpha 7 homology model, Bt or Ac crystal structure is used. (C) 2011 Elsevier Masson SAS. All rights reserved.
• Discovery of novel α7 nicotinic acetylcholine receptor ligands via pharmacophoric and docking studies of benzylidene anabaseine analogs
  作者：David C. Kombo、Anatoly A. Mazurov、Joseph Chewning、Philip S. Hammond、Kartik Tallapragada、Terry A. Hauser、Jason Speake、Daniel Yohannes、William S. Caldwell

  DOI：10.1016/j.bmcl.2011.11.090

  日期：2012.1

  Based on pharmacophore elucidation and docking studies on interactions of benzylidene anabaseine analogs with AChBPs and alpha 7 nAChR, novel spirodiazepine and spiroimidazoline quinuclidine series have been designed. Binding studies revealed that some of hydrogen-bond donor containing compounds exhibit improved affinity and selectivity for the alpha 7 nAChR subtype in comparison with most potent metabolite of GTS-21, 3-(4-hydroxy-2-methoxybenzylidene)-anabaseine. Hydrophobicity and rigidity of the ligand also contribute into its binding affinity. We also describe alternative pharmacophoric features equidistant from the carbonyl oxygen atom of the conserved Trp-148 of the principal face, which may be exploited to further design diverse focused libraries targeting the alpha 7 nAChR. (C) 2011 Elsevier Ltd. All rights reserved.